What Has Been the Growth of the Parathyroid Hormone Market So Far?
The parathyroid hormone market has seen considerable growth due to a variety of factors.
• In the past few years, there has been a consistent growth in the parathyroid hormone market size. The industry, which is projected to expand from $2.35 billion in 2024 to $2.43 billion in 2025, is expected to experience a 3.5% compound annual growth rate (CAGR). The surge during the historical period is credited to the escalating occurrence of chronic kidney disease, heightened awareness about disorders related to parathyroid hormone, increased requirement for parathyroid hormone analogs, robust government financial support for the study of parathyroid hormone, and the rise in disposable incomes.
What Is the Forecasted Market Size and Growth Rate for The Parathyroid Hormone Market Size In The Coming Years?
The parathyroid hormone market is expected to maintain its strong growth trajectory in upcoming years.
• The market for parathyroid hormone is anticipated to witness robust expansion in the forthcoming years. The value is projected to reach $3.5 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.6%.
Factors contributing to the growth in the predicted period include a rising elderly population, expansion of private healthcare sectors, emerging indications, precision medicine, increasing awareness of bone health, and broader healthcare access. Noticeable trends during the forecast period include progression in parathyroid hormone testing, improvements in drug delivery, combination therapies, integration of digital health, and focus on sustainability and green initiatives.
What Factors Are Driving Growth In The Parathyroid Hormone Market?
With an expected surge in osteoporosis cases, the market for parathyroid hormones anticipates significant growth. Osteoporosis, a condition marked by a decrease in bone mass and worsening bone tissue, amplifies the chance of fractures. As an illustration, the International Osteoporosis Foundation stated in January 2023 that around 1.4 million Canadians, primarily postmenopausal women and aged people, are afflicted by osteoporosis. Parathyroid hormone, a natural body-produced hormone controlling calcium levels, is utilized to lower the fracture risks in osteoporosis patients through daily subcutaneous injections. Hence, the rising incidence of osteoporosis is projected to foster the expansion of the parathyroid hormone market.
What Are The Main Segments Of The Global Parathyroid Hormone Market?
The parathyroid hormone market covered in this report is segmented –
1) By Disease Type: Hypocalcemia, Hypoparathyroidism
2) By Product Type: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues
3) By End-User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Hypocalcemia: Pseudohypoparathyroidism, Vitamin D Deficiency
2) By Hypoparathyroidism: Post-Surgical Hypoparathyroidism, Idiopathic Hypoparathyroidism
Pre-Book The Parathyroid Hormone Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Parathyroid Hormone Industry?
Leading firms in the parathyroid hormone market have their sights set on producing biosimilars like prodrugs of parathyroid hormone, in an effort to broaden the range of treatment choices. Prodrugs of parathyroid hormone are inactive substances, which turn into active parathyroid hormone upon administration, providing sustained release and steady medical results for calcium management and the wellbeing of bones. To illustrate, Ascendis Pharma A/S, a Denmark-based biopharmaceutical firm, announced in August 2024 that the Food & Drug Administration (FDA) validated YORVIPATH (palopegteriparatide) as the unique treatment available for hypoparathyroidism in adults. Administered once per day, this prodrug provides consistent PTH exposure, impacting an estimated 70,000 to 90,000 patients in the U.S. Ascendis Pharma offers patient assistance via its Ascendis Signature Access Program (A.S.A.P.), but users have to frequently check serum calcium levels for possible hypercalcemia or hypocalcemia.
Who Are the Key Players In The Parathyroid Hormone Market?
Major companies operating in the parathyroid hormone market include:
• Pfizer Inc.
• Eli Lilly and Company
• Radius Health Inc.
• Ascendis Pharma
• Entera Bio Ltd.
• Extend Biosciences Inc.
• Gedeon Richter Plc.
• Abbott Laboratories
• Amgen Inc.
• Merck & Co. Inc.
• Novartis AG
• F. Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd.
• Alcon Laboratories Inc.
• Bayer Healthcare
• AstraZeneca PLC
• Biocon
• Dr. Reddy's Laboratories
• Glenmark Pharmaceuticals
• Jubilant Life Sciences
• Lupin Limited
• Sun Pharmaceutical Industries
• Torrent Pharmaceuticals
• Wockhardt
• Cipla Limited
What Is The Most Dominant Region In The Parathyroid Hormone Market?
North America was the largest region in the parathyroid hormone market in 2024. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market share during the forecast period. The regions covered in the parathyroid hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
